FIGURE 6.

Regulatory pathways of the antifibrotic evaluation of erlotinib in cirrhotic PCLS. Quantitative RT-PCR analysis of the mRNA expression on (A) antifibrotic pathways, (B) profibrotic pathways, and (C) inhibitory pathways of MMPs in PCLS from CDAHFD-induced cirrhosis mice after erlotinib treatment for 72 hours. (D) These experiments were repeated 3 times (n = 4) and summarized in the form of a heatmap. (E) Quantitative RT-PCR analysis on additional regulatory genes for fibrosis generation and degradation. All values were expressed as the mean ± SEM with 2-tailed Student t tests. Significance is represented by *p < 0.05, ***p < 0.001, ns indicates not significant. Abbreviations: CDAHFD, choline-deficient, l-amino acid–defined, high-fat diet; MMP, matrix metalloproteinase; PCLS, precision-cut liver slices; RT-PCR, reverse transcription quantitative polymerase chain reaction.